Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia — Stella

Recruiting

Back to T-Cell Large Granular Lymphocyte Leukemia trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(3 sites)

United States

Dana-Farber Cancer Institute, Boston, Massachusetts

Memorial Sloan Kettering Cancer Center, New York, New York

Ohio State University Comprehensive Cancer Center, Columbus, Ohio

Key details

Phase

Safety & dosing

Sponsor

Jonathan Brammer

Enrollment target

~30 participants

Started

May 2023

Primary completion

July 2026

Age range

18 Years and older

Last updated February 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov